Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova (TKNO)
NASDAQ:TKNO
TKNO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.94 - $10.37
Previous CloseN/A
Volume51.57K
Average Volume (3M)204.25K
Market Cap
$235.47M
Enterprise Value$267.40M
Total Cash (Recent Filing)$3.28M
Total Debt (Recent Filing)$15.94M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 05, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding53,515,167
10 Day Avg. Volume184,085
30 Day Avg. Volume204,252
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue6.87
Enterprise Value/Gross Profit29.04
Enterprise Value/Ebitda-14.70
Forecast
1Y Price Target
$8.63Price Target Upside85.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTeknova continues to execute admirably in a challenging environment, beating expectations across the board, maintaining revenue guidance, and increasing gross margin guidance.
Market PositionTeknova is viewed as one of the best-positioned small-cap names to benefit when and if end-markets begin to improve.
Revenue GrowthTeknova's diversified revenue base, custom-to-catalog shift, and minimal NIH and tariff exposure position them to weather the CGT market effectively.
Bears Say
Macroeconomic ChallengesDue to some challenges at the macro level in life sciences, modest current expected top-line growth, and the stock's premium valuation relative to its small cap peer group, the Neutral rating on TKNO is maintained.
Valuation ConcernsShares of TKNO trade at a premium to the small cap tools peer group.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $3.94 and its highest was $10.37 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $235.47M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is Nov 05, 2025 which is in 45 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on Aug 07, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.03.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Undervalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.09.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,515,167 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -2.535%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
Alpha Teknova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.63 (85.99% Upside)
$8.63 (85.99% Upside)
Hedge Fund Trend
Decreased
By 275.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.38%
12-Months-Change
Fundamentals
Return on Equity
-27.74%
Trailing 12-Months
Asset Growth
-4.22%
Trailing 12-Months
Company Description
Alpha Teknova
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with both positive growth metrics and ongoing challenges. While revenue and clinical solutions showed strong growth and operational efficiencies improved gross margins, the company continues to face challenges with a negative adjusted EBITDA and lower-than-expected growth in custom products. The overall sentiment reflects cautious optimism with significant progress in some areas, but ongoing challenges in others.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
$8.63
▲(85.99% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
SIGA Technologies
―
Aquestive Therapeutics
―
Ownership Overview
1.19% Insiders
1.63% Mutual Funds
3.03% Other Institutional Investors
92.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---